AA
RDY icon

ALPS Advisors’s Dr. Reddy's Laboratories RDY Stock Holding History

ALPS Advisors’s Portfolio RDY Stock Details RDY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$884K Buy
63,836
+800
+1% +$11.1K ﹤0.01% 600
2025
Q4 		$885K Buy
+63,036
New +$884K 0.01% 587
2024
Q4 		– Sell
-33,310
Closed -$529K – 1030
2024
Q3 		$529K Sell
33,310
-1,500
-4% -$24.1K ﹤0.01% 601
2024
Q2 		$530K Buy
34,810
+800
+2% +$11.5K ﹤0.01% 568
2024
Q1 		$499K Sell
34,010
-7,465
-18% -$109K ﹤0.01% 592
2023
Q4 		$577K Sell
41,475
-14,790
-26% -$198K ﹤0.01% 583
2023
Q3 		$752K Sell
56,265
-8,310
-13% -$112K 0.01% 536
2023
Q2 		$815K Sell
64,575
-2,510
-4% -$29.3K 0.01% 528
2023
Q1 		$764K Buy
67,085
+16,585
+33% +$179K 0.01% 519
2022
Q4 		$523K Buy
+50,500
New +$545K ﹤0.01% 581
2021
Q4 		– Sell
-39,860
Closed -$519K – 961
2021
Q3 		$519K Buy
39,860
+4,400
+12% +$58.6K 0.01% 494
2021
Q2 		$521K Sell
35,460
-2,765
-7% -$38.7K ﹤0.01% 511
2021
Q1 		$469K Buy
38,225
+5,525
+17% +$71K ﹤0.01% 493
2020
Q4 		$466K Buy
+32,700
New +$440K 0.01% 509
2019
Q4 		– Sell
-81,725
Closed -$619K – 852
2019
Q3 		$619K Sell
81,725
-2,995
-4% -$22.3K ﹤0.01% 455
2019
Q2 		$635K Sell
84,720
-1,425
-2% -$11.2K ﹤0.01% 484
2019
Q1 		$698K Buy
86,145
+4,455
+5% +$33.8K ﹤0.01% 411
2018
Q4 		$616K Buy
+81,690
New +$575K ﹤0.01% 432
2017
Q4 		– Sell
-142,380
Closed -$1.02M – 877
2017
Q3 		$1.02M Buy
142,380
+32,750
+30% +$235K 0.01% 239
2017
Q2 		$924K Buy
109,630
+45,085
+70% +$367K 0.01% 234
2017
Q1 		$518K Buy
64,545
+27,740
+75% +$240K ﹤0.01% 373
2016
Q4 		$333K Buy
36,805
+1,320
+4% +$12.3K ﹤0.01% 660
2016
Q3 		$329K Buy
35,485
+335
+1% +$3.2K ﹤0.01% 637
2016
Q2 		$360K Buy
35,150
+12,635
+56% +$116K ﹤0.01% 532
2016
Q1 		$203K Buy
+22,515
New +$201K ﹤0.01% 604

Other funds holding RDY

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
Aikya Investment Management London, United Kingdom $345M AUM 10.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

ALPS Advisors's RDY Position: Q1 2026 in Review

ALPS Advisors increased its Dr. Reddy's Laboratories (RDY) stake by 1.3% in Q1 2026, buying an estimated $11.1K and bringing the position to 63,836 shares worth $884K. The position accounts for ﹤0.01% of the portfolio, ranked #600.

ALPS Advisors first reported a position in RDY in Q1 2016 and has held it in 25 quarters since. The position peaked at $1.02M in Q3 2017. 247 funds tracked by Wall St. Rank hold RDY as of Q1 2026.

  • ALPS Advisors held 63,836 shares of Dr. Reddy's Laboratories worth $884K as of Q1 2026.
  • ALPS Advisors bought 800 Dr. Reddy's Laboratories shares in Q1 2026, an estimated $11.1K.
  • Dr. Reddy's Laboratories made up ﹤0.01% of ALPS Advisors's portfolio in Q1 2026, its #600 holding.
  • ALPS Advisors first reported a position in Dr. Reddy's Laboratories in Q1 2016 and has held it in 25 quarters since.
  • ALPS Advisors's Dr. Reddy's Laboratories position peaked at $1.02M in Q3 2017.
  • 247 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q1 2026.

Based on ALPS Advisors's 13F filing for Q1 2026, filed 8 May 2026.